<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6831519</article-id><article-id pub-id-type="doi">10.3389/fimmu.2019.02471</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Case Report</subject></subj-group></subj-group></article-categories><title-group><article-title>Novel Compound Heterozygous Mutations in <italic>IL-7 Receptor</italic> &#x003b1; Gene in a 15-Month-Old Girl Presenting With Thrombocytopenia, Normal T Cell Count and Maternal Engraftment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zangari</surname><given-names>Paola</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/741487/overview"/></contrib><contrib contrib-type="author"><name><surname>Cifaldi</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Di Cesare</surname><given-names>Silvia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/397177/overview"/></contrib><contrib contrib-type="author"><name><surname>Di Matteo</surname><given-names>Gigliola</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="c002"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/397175/overview"/></contrib><contrib contrib-type="author"><name><surname>Chiriaco</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/635925/overview"/></contrib><contrib contrib-type="author"><name><surname>Amodio</surname><given-names>Donato</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cotugno</surname><given-names>Nicola</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/428772/overview"/></contrib><contrib contrib-type="author"><name><surname>De Luca</surname><given-names>Maia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/507338/overview"/></contrib><contrib contrib-type="author"><name><surname>Surace</surname><given-names>Cecilia</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ladogana</surname><given-names>Saverio</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gardini</surname><given-names>Simone</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Merli</surname><given-names>Pietro</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Algeri</surname><given-names>Mattia</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rossi</surname><given-names>Paolo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/155450/overview"/></contrib><contrib contrib-type="author"><name><surname>Palma</surname><given-names>Paolo</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/433162/overview"/></contrib><contrib contrib-type="author"><name><surname>Cancrini</surname><given-names>Caterina</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/453401/overview"/></contrib><contrib contrib-type="author"><name><surname>Finocchi</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/69818/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Unit of Immune and Infectious Diseases, Academic Department of Pediatrics, Bambino Ges&#x000f9; Children's Hospital, IRCCS</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Systems Medicine, University of Rome Tor Vergata</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff><aff id="aff3"><sup>3</sup><institution>Research Unit in Congenital and Perinatal Infections, Unit of Immune and Infectious Diseases, Academic Department of Pediatrics, Ospedale Pediatrico Bambino Ges&#x000f9;, IRCCS</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff><aff id="aff4"><sup>4</sup><institution>Laboratory of Medical Genetics Unit, Bambino Ges&#x000f9; Children's Hospital, IRCCS</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff><aff id="aff5"><sup>5</sup><institution>Paediatric Onco-Haematology Unit, Casa Sollievo della Sofferenza Hospital, IRCCS</institution>, <addr-line>San Giovanni Rotondo</addr-line>, <country>Italy</country></aff><aff id="aff6"><sup>6</sup><institution>GenomeUp SRL</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff><aff id="aff7"><sup>7</sup><institution>Department of Pediatric Hematology and Oncology, Bambino Ges&#x000f9; Children's Hospital, IRCCS</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Yu Lung Lau, The University of Hong Kong, Hong Kong</p></fn><fn fn-type="edited-by"><p>Reviewed by: John Bernard Ziegler, Sydney Children's Hospital, Australia; Hirokazu Kanegane, Tokyo Medical and Dental University, Japan; Paul Edgar Gray, Sydney Children's Hospital, Australia</p></fn><corresp id="c001">*Correspondence: Paola Zangari <email>paola.zangari@opbg.net</email></corresp><corresp id="c002">Gigliola Di Matteo <email>di.matteo@med.uniroma2.it</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Primary Immunodeficiencies, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>30</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>10</volume><elocation-id>2471</elocation-id><history><date date-type="received"><day>25</day><month>6</month><year>2019</year></date><date date-type="accepted"><day>03</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2019 Zangari, Cifaldi, Di Cesare, Di Matteo, Chiriaco, Amodio, Cotugno, De Luca, Surace, Ladogana, Gardini, Merli, Algeri, Rossi, Palma, Cancrini and Finocchi.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Zangari, Cifaldi, Di Cesare, Di Matteo, Chiriaco, Amodio, Cotugno, De Luca, Surace, Ladogana, Gardini, Merli, Algeri, Rossi, Palma, Cancrini and Finocchi</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Patients with severe combined immunodeficiency (SCID) exhibit T lymphopenia and profound impairments in cellular and humoral immunity. IL-7 receptor &#x003b1; (IL-7R&#x003b1;) deficiency is a rare form of SCID that usually presents in the first months of life with severe and opportunistic infections, failure to thrive and high risk of mortality unless treated. Here, we reported an atypical and delayed onset of IL7R&#x003b1;-SCID in a 15-month-old girl presenting with thrombocytopenia. Immunological investigations showed a normal lymphocyte count with isolated CD4-penia, absence of na&#x000ef;ve T cells, marked hypergammaglobulinemia, and maternal T cell engraftment. Targeted next generation sequencing (NGS) revealed two novel compound heterozygous mutations in the <italic>IL-7R</italic>&#x003b1; gene: c.160T&#x0003e;C (p.S54P) and c.245G&#x0003e;T (p.C82F). The atypical onset and the unusual immunological phenotype expressed by our patient highlights the diagnostic challenge in the field of primary immunodeficiencies (PID) and in particular in SCID patients where prompt diagnosis and therapy greatly affects survival.</p></abstract><kwd-group><kwd>SCID</kwd><kwd><italic>IL-7R</italic>&#x003b1; gene</kwd><kwd>novel compound heterozygous mutations</kwd><kwd>atypical onset</kwd><kwd>maternal engraftment</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Fondazione Telethon<named-content content-type="fundref-id">10.13039/501100002426</named-content></funding-source></award-group><award-group><funding-source id="cn002">Ministero della Salute<named-content content-type="fundref-id">10.13039/501100003196</named-content></funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="1"/><equation-count count="0"/><ref-count count="19"/><page-count count="6"/><word-count count="3729"/></counts></article-meta></front><body><sec id="s1"><title>Highlights</title><list list-type="simple"><list-item><p>- Normal T cell count with isolated CD4-penia and thrombocytopenia in a SCID patient.</p></list-item><list-item><p>- Novel compound heterozygous mutations in IL-7 receptor &#x003b1; deficiency.</p></list-item><list-item><p>- Maternal T cell engraftment.</p></list-item></list></sec><sec id="s2"><title>Background</title><p>Severe combined immunodeficiency (SCID) represents a heterogeneous group of primary immunodeficiencies with a severe impairment of T cell function and variable functional or quantitative B and natural killer (NK) cell defects, leading to severe and opportunistic infections within the first months of life (<xref rid="B1" ref-type="bibr">1</xref>). Interleukin-7 (IL-7) is essential for T cell development in the thymus and for maintaining and restoring the homeostasis of mature T cells, but it is redundant for human B and NK cell development. The IL-7 receptor (IL-7R) is a heterodimer, consisting of two subunits, the IL-7R&#x003b1; chain (CD127) and common-&#x003b3; chain (CD132). The binding of IL-7 to the IL-7R&#x003b1; chain leads to dimerization with the common-&#x003b3; chain and a subsequent activation of the Janus kinase&#x02013;signal transducer and activator of the transcription (JAK&#x02013;STAT) pathway (<xref rid="B2" ref-type="bibr">2</xref>). <italic>IL-7R</italic>&#x003b1; mutation is responsible of about 10% of SCID and generally causes an early onset SCID with a T- B+ NK+ immunophenotype (<xref rid="B3" ref-type="bibr">3</xref>). Besides typical characteristics of the SCID phenotype, <italic>IL-7R</italic>&#x003b1; mutations could manifest later with a milder clinical presentation and rarely with immune dysregulation such as autoimmune cytopenia or Omenn syndrome (OS) (<xref rid="B4" ref-type="bibr">4</xref>&#x02013;<xref rid="B6" ref-type="bibr">6</xref>). Moreover, patients with SCID do not usually recognize and reject foreign cells, and maternal engrafted T cells were therefore detected in up to 40% of patients (<xref rid="B7" ref-type="bibr">7</xref>). In the majority of these cases, maternal engraftment is asymptomatic, however some infants can manifest signs and symptoms of graft-versus-host-disease (GVHD) with cutaneous involvement, liver injury, and hematologic abnormalities. Here, we report a 15-month-old girl with an atypical presentation of thrombocytopenia, isolated CD4-penia, hypergammaglobulinemia and maternal T-cell engraftment who was found to have two novel compound heterozygous mutations in <italic>IL-7R</italic>&#x003b1;.</p></sec><sec id="s3"><title>Case Presentation</title><p>A 15-month-old Caucasian girl born from non-consanguineous parents with an uneventful dizygotic twin pregnancy, good birth weight, and healthy twin sister was referred to our hospital due to mild atopic dermatitis and recurrent upper respiratory infections.</p><p>There was no known family history of immunodeficiency, the baby had normal psychomotor development and there was no failure to thrive.</p><p>At 10 months of age she experienced periorbital edema due to primary EBV infection as confirmed by blood EBV PCR and subsequent hypertransaminasemia. At 12 months of age she was hospitalized for immune thrombocytopenic purpura, which was successfully treated with high-dose intravenous immunoglobulin (IVIG).</p><p>At the time of our evaluation, immunological investigations revealed a normal count of total lymphocytes (4,300 cells/mm<sup>3</sup>), severely reduced numbers of CD3<sup>+</sup>CD4<sup>+</sup> (184 cells/mm<sup>3</sup>) with barely detectable CD4<sup>+</sup> CD45RA<sup>+</sup> CD27+ na&#x000ef;ve T cells and CD4<sup>+</sup> CD45RA<sup>+</sup> CD31+ recent thymic emigrants (RTE). <italic>In vitro</italic> T-cell proliferation in response to phytohemagglutinin (PHA) and anti-OKT3 was severely decreased. Despite her marked hypergammaglobulinemia, partially impaired humoral immunity with reduced pneumococcal IgG titer (total pneumococcal IgG ELISA Binding Site) after vaccinations (Prevnar13, two doses), lower peripheral B cells with reduced transitional B cells and increased plasma cells were found. Interestingly, protective antibody titers to tetanus and to Haemophilus influenzae type B (Hib) immunization were detected (<xref rid="T1" ref-type="table">Table 1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Patient's immunological investigations.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><bold>Patient value</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Normal age-matched value</bold></th></tr></thead><tbody><tr><td valign="top" align="left" colspan="3" style="background-color:#bdbec1" rowspan="1"><bold>COMPLETE BLOOD COUNT</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Complete blood count</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">White blood cell (103/&#x003bc;l)</td><td valign="top" align="center" rowspan="1" colspan="1">10.41</td><td valign="top" align="center" rowspan="1" colspan="1">6.00&#x02013;17.00</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Red blood cells (106/&#x003bc;l)</td><td valign="top" align="center" rowspan="1" colspan="1">4.27</td><td valign="top" align="center" rowspan="1" colspan="1">3.60&#x02013;5.00</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Neutrophils (103/&#x003bc;l)</td><td valign="top" align="center" rowspan="1" colspan="1">3.47</td><td valign="top" align="center" rowspan="1" colspan="1">1.68&#x02013;8.50</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lymphocytes (103/&#x003bc;l)</td><td valign="top" align="center" rowspan="1" colspan="1">4.38</td><td valign="top" align="center" rowspan="1" colspan="1">3.6&#x02013;8.9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Platelets (103/&#x003bc;l)</td><td valign="top" align="center" rowspan="1" colspan="1">371</td><td valign="top" align="center" rowspan="1" colspan="1">150&#x02013;450</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hemoglobin (g/dl)</td><td valign="top" align="center" rowspan="1" colspan="1">11</td><td valign="top" align="center" rowspan="1" colspan="1">10.5&#x02013;15.5</td></tr><tr><td valign="top" align="left" colspan="3" style="background-color:#bdbec1" rowspan="1"><bold>LYMPHOCYTE SUBSET</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Absolute CD3+</td><td valign="top" align="center" rowspan="1" colspan="1">2400</td><td valign="top" align="center" rowspan="1" colspan="1">2,100&#x02013;6,200</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Absolute CD4+</td><td valign="top" align="center" rowspan="1" colspan="1">184</td><td valign="top" align="center" rowspan="1" colspan="1">1,300&#x02013;3,400</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Absolute CD8+</td><td valign="top" align="center" rowspan="1" colspan="1">2012</td><td valign="top" align="center" rowspan="1" colspan="1">620&#x02013;2,000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Absolute CD16+CD56+</td><td valign="top" align="center" rowspan="1" colspan="1">1505</td><td valign="top" align="center" rowspan="1" colspan="1">720&#x02013;2,600</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Absolute CD19+ cells/mL</td><td valign="top" align="center" rowspan="1" colspan="1">283</td><td valign="top" align="center" rowspan="1" colspan="1">720&#x02013;2,600</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD19+CD24+CD38+ cells/mL (Transitional B)</td><td valign="top" align="center" rowspan="1" colspan="1">18</td><td valign="top" align="center" rowspan="1" colspan="1">56&#x02013;101</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD19+CD24-CD38+ cells/mL (Plasma cells)</td><td valign="top" align="center" rowspan="1" colspan="1">70</td><td valign="top" align="center" rowspan="1" colspan="1">40&#x02013;55</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD3+CD4+CD27+CD45RA+% (na&#x000cf;ve)</td><td valign="top" align="center" rowspan="1" colspan="1">0.3</td><td valign="top" align="center" rowspan="1" colspan="1">63&#x02013;91</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD3+CD4+CD27+CD45RA-% (CM)</td><td valign="top" align="center" rowspan="1" colspan="1">66.3</td><td valign="top" align="center" rowspan="1" colspan="1">10&#x02013;26</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD3+CD4+CD27-CD45RA-% (EM)</td><td valign="top" align="center" rowspan="1" colspan="1">33.4</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x02013;16</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD3+CD4+C27-CD45RA+% (TEMRA)</td><td valign="top" align="center" rowspan="1" colspan="1">0.1</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x02013;12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD3+CD4+CD31+CD45RA+% (RTE)</td><td valign="top" align="center" rowspan="1" colspan="1">0.2</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;40</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD3+CD8+CCR7+CD45RA+ % (na&#x000cf;ve)</td><td valign="top" align="center" rowspan="1" colspan="1">0.07</td><td valign="top" align="center" rowspan="1" colspan="1">71&#x02013;98</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD3+CD8+CCR7+CD45RA-% (CM)</td><td valign="top" align="center" rowspan="1" colspan="1">0.24</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x02013;15</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD3+CD8+CCR7-CD45RA-% (EM)</td><td valign="top" align="center" rowspan="1" colspan="1">97.9</td><td valign="top" align="center" rowspan="1" colspan="1">9&#x02013;47</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD3+CD8+CCR7-CD45RA+% (TEMRA)</td><td valign="top" align="center" rowspan="1" colspan="1">1.7</td><td valign="top" align="center" rowspan="1" colspan="1">7&#x02013;25</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD3+ TCR alpha-beta</td><td valign="top" align="center" rowspan="1" colspan="1">96</td><td valign="top" align="center" rowspan="1" colspan="1">26&#x02013;100</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD3+ TCR gamma-delta</td><td valign="top" align="center" rowspan="1" colspan="1">3.6</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x02013;13</td></tr><tr><td valign="top" align="left" colspan="3" style="background-color:#bdbec1" rowspan="1"><bold>LYMPHOCYTE STIMULATION TO MITOGENS (cpm)</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Phytohemagglutinin</td><td valign="top" align="center" rowspan="1" colspan="1">2.788</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;35.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">OKT3</td><td valign="top" align="center" rowspan="1" colspan="1">4.838</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;25.000</td></tr><tr><td valign="top" align="left" colspan="3" style="background-color:#bdbec1" rowspan="1"><bold>SERUM IMMUNOGLOBULIN LEVELS</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IgG (mg/dL)</td><td valign="top" align="center" rowspan="1" colspan="1">3,603</td><td valign="top" align="center" rowspan="1" colspan="1">264&#x02013;1,509</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IgA (mg/dL)</td><td valign="top" align="center" rowspan="1" colspan="1">680</td><td valign="top" align="center" rowspan="1" colspan="1">17&#x02013;178</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IgM (mg/dL)</td><td valign="top" align="center" rowspan="1" colspan="1">509</td><td valign="top" align="center" rowspan="1" colspan="1">48&#x02013;337</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IgE (IU/mL)</td><td valign="top" align="center" rowspan="1" colspan="1">2.9</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;2</td></tr><tr><td valign="top" align="left" colspan="3" style="background-color:#bdbec1" rowspan="1"><bold>ANTIBODY RESPONSE TO VACCINATIONS</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tetanus titer (IU/mL)</td><td valign="top" align="center" rowspan="1" colspan="1">0.13</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;0.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Haemophilus titer (mg/l)</td><td valign="top" align="center" rowspan="1" colspan="1">0.2</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;0.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Post-pneumococcal titer (mg/l)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;3</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;35</td></tr></tbody></table><table-wrap-foot><p><italic>CM, central memory; EM, effector memory; TEMRA, terminally differentiated effector memory; RTE, recent thymic emigrants</italic>.</p></table-wrap-foot></table-wrap><p>Microbiological tests revealed negative HIV serology and incomplete seroconversion against EBV (IgG anti-VCA present, IgM anti-VCA absent, IgG anti-EBNA absent) with a high level of EBV replication.</p><p>Chest CT showed hypoplasic thymus, multiple bilateral nodular lesions with ground glass appearance and 6,000,000 copies/mL of EBV in bronchoalveolar lavage. No other significant pathogens were identified. An abdomen ultrasound documented hepatomegaly and blood tests revealed hypertransaminasemia with normal markers of liver synthetic function.</p><p>Moreover, due to the persistence of eczematous dermatitis, a skin biopsy was performed that revealed psoriasiform epidermal hyperplasia, focal spongiosis, and parakeratosis and an inflammatory mononuclear dermal infiltrate with the following immunohistochemical profile: CD20<sup>&#x02212;</sup>; CD3<sup>+</sup>; CD8<sup>+/&#x02212;</sup>; CD4<sup>&#x02212;/+</sup>; CD68<sup>&#x02212;/+</sup>; CD1a<sup>+</sup>.</p><p>In view of the marked CD4-penia with almost absent recent RTE, the concomitant expansion of the CD4<sup>+</sup> and CD8<sup>+</sup>memory T lymphocytes and the cutaneous histopathology a diagnosis of SCID with maternal T-cell engraftment was suspected. The variable number of tandem repeat analysis performed on both peripheral blood and the skin biopsy revealed that all T lymphocytes (CD4<sup>+</sup> and CD8<sup>+</sup>) in the patient were of maternal origin while CD19<sup>+</sup> and CD16<sup>+</sup>CD56<sup>+</sup> cells were autologous (<xref ref-type="supplementary-material" rid="SM2">Supplementary Figure 2</xref>).</p><p>Targeted NGS (Ion Torrent), revealed two novel compound heterozygous mutations in <italic>IL-7R</italic>&#x003b1; gene confirmed by Sanger sequencing (<xref ref-type="fig" rid="F1">Figure 1A</xref>). The c.160T&#x0003e;C (p.S54P) was predicted to be damaging by SIFT and PROVEAN, probably damaging by Polyphen whereas CADD assigned a score of 18, predicting this variant as likely benign. The second mutation, c.245G&#x0003e;T (p.C82F), is predicted to be damaging by all pathogenicity prediction tools. Phylogenetic and amino acid conservation analyses, when available, showed that the serine at position 54 was conserved in many amniota vertebrates but changed to leucine in pig, dog, marmot, and other species, whereas the cysteine at position 82 was well-conserved.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>(A)</bold> Sequence alignment of the patient's BAM file on IGV (Integrative Genomics Viewer) and the two heterozygous mutation found by <italic>IL7R</italic> DNA sequencing. <bold>(B)</bold> Patient's genealogical tree.</p></caption><graphic xlink:href="fimmu-10-02471-g0001"/></fig><p>To investigate the potential consequences of these mutations to the protein stability and structure we analyzed the 3D-structure of Interleukin-7 receptor subunit alpha (IL7R&#x02014;UniProtKB:P16871) (<xref rid="B8" ref-type="bibr">8</xref>). The X-ray-resolved structure of IL7R was retrieved from the Protein Data Bank with the PDB ID code 3UP1 (<xref rid="B9" ref-type="bibr">9</xref>). The structural features of the IL7R were analyzed with Open source PyMOL v. 1.7.1.0. (<xref rid="B10" ref-type="bibr">10</xref>). The C82 was involved in disulfide bond formation with C74 (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figure 1A</xref>) and the S54 was involved in moderate electrostatic bond formation with Q45 (hydrogen bond distance 2.7A, <xref ref-type="supplementary-material" rid="SM1">Supplementary Figure 1B</xref>), both destabilizing the IL7R antiparallel beta-sheets.</p><p>For the protein stability prediction, we performed the mCSM tool (<xref rid="B11" ref-type="bibr">11</xref>), and the predicted stability change (&#x00394;&#x00394;G) was &#x02212;0.895 Kcal/mol (Destabilizing) and &#x02212;0.816 Kcal/mol (Destabilizing), respectively.</p><p>The pedigree analysis indicated the presence of the p.C82F mutation in the mother, and the p.S54P mutation in the father and the proband's sister (<xref ref-type="fig" rid="F1">Figure 1B</xref>).</p><p>The IL-7R&#x003b1; expression was reduced in total CD3<sup>+</sup> T cells with a bimodal pattern explained by normal expression on CD3<sup>+</sup>CD4<sup>+</sup>cells (data not showed) and marked reduction on CD3<sup>+</sup>CD4<sup>&#x02212;</sup> T cells (<xref ref-type="fig" rid="F2">Figure 2</xref>). In line with these results, STAT5 phosphorylation in response to IL-7 stimulation (50 ng/mL) was reduced in total CD3<sup>+</sup>, normal in CD3<sup>+</sup>CD4<sup>+</sup>cells and almost absent in CD3<sup>+</sup>CD4<sup>&#x02212;</sup> T lymphocytes compared to her parents (<xref ref-type="fig" rid="F2">Figure 2</xref>). Regular intravenous immunoglobulin and prophylactic antimicrobial therapy were administered from the time of the diagnosis.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Phenotypic and pSTAT5 signaling in patient's relatives and in patient derived lymphocytes. <bold>(A)</bold> IL-7R&#x003b1; (CD 127) surface expression were assessed by means of multiparameter flow cytometry in T cell subset. <bold>(B)</bold> The phosphorylation status of STAT5 (Y694) was determined by means of Phosflow analysis after IL-7 treatment in T cell subsets.</p></caption><graphic xlink:href="fimmu-10-02471-g0002"/></fig><p>She received a short course of intravenous corticosteroids (three doses of methylprednisolone 15 mg/kg) with a rapid improvement of the dermatitis.</p><p>In order to control the EBV replication she received four doses of Rituximab (375 mg/m<sup>2</sup>) with viremia reduction and a full recovery in lung parenchyma was confirmed with a subsequent chest CT.</p><p>The patient underwent hematopoietic stem cell transplantation (HSCT) from an HLA-haploidentical donor (her mother) after negative depletion of T&#x003b1;&#x003b2;+/CD19+ lymphocytes. The conditioning regimen included treosulfan, fludarabine, anti-T-lymphocyte globulin, and rituximab; no post-transplant pharmacological graft-versus-host disease (GVHD) prophylaxis was employed. The median time to reach neutrophil and platelet engraftment was 31 and 11 days, respectively. No toxicities or serious adverse events occurred. A total of 35 months after the allograft she is in good clinical conditions and without GVHD.</p></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>IL-7R&#x003b1; deficiency represents ~10% of SCID cases. IL-7 signaling is essential for normal T-cell development leading to the activation of the phosphatidylinositol-3-kinase (PI3K), the Ras/Raf signaling cascade and Janus kinase/STAT pathways (STAT5 and STAT3) (<xref rid="B2" ref-type="bibr">2</xref>). Typically, patients with complete IL-7R&#x003b1; deficiency present early onset SCID with profound T cell lymphopenia and abnormal T-cell function. B-cell levels are typically normal, but immunoglobulin production is usually decreased due to T cell dysfunction. Our patient showed an atypical IL-7R&#x003b1;-deficient SCID phenotype, including later onset, isolated CD4-penia with a normal T cell count and hypergammaglobulinemia. Profound or moderate T cell lymphopenia have been reported in all patients affected by IL-7R&#x003b1; deficiency (<xref rid="B12" ref-type="bibr">12</xref>&#x02013;<xref rid="B14" ref-type="bibr">14</xref>). In our case the immunological features suggesting a combined immunodeficiency were the severely reduced number of circulating CD4+ T lymphocytes, the na&#x000ef;ve CD4+ T cells absence, the defective T-cell proliferation and the abnormal peripheral B-cell subset distribution. Of note was the fact that the absolute lymphocyte count and &#x003b3;&#x003b4; T cells were normal.</p><p>Using NGS techniques we detected the presence of two probable pathogenic novel compound mutations, the p.S54P and the p.C82F both destabilizing the IL7R protein structure. Pathogenicity of the cysteine (C82F) and the serine (S54P) replacements can be attributed to the structural role of these amino acids. Cysteine is often involved in disulphide bonds, where these bonds stabilize the protein structure. The structure of many extracellular proteins is stabilized by the topology of multiple disulphide bonds. IL7R have three disulfide bonds and one extracellular region. The serine 54 was found in a common motif of the secondary structure, the beta-sheet. Proline can often be found in the secondary structures as there is a turn when the chain must modify its direction. We have therefore hypothesized that these two mutations have a destabilizing and damaging effect. The deleterious effect of these mutations is supported by the maternal engraftment observed in our patient, underlining a compromised immune system that is probably due to an impaired IL7R&#x003b1; function. Moreover, we had previously ruled out the presence of mutations in 40 genes known to be associated with SCID-CID phenotypes included in the targeted NGS panel used in this study. However, we can't exclude the presence of mutations in other genes not included in the analysis. The maternal engraftment could have had an impact on the atypical phenotype and definitively on the circulating lymphocyte count. Maternal engraftment occurred in ~40% of patients with T- B+ NK- SCID. Notably, a variable frequency in different studies has been previously reported in IL-7R&#x003b1;-deficient patients (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B12" ref-type="bibr">12</xref>). The engrafted T cells are usually oligoclonal memory/effector cells, which are non-functional based on <italic>in vitro</italic> studies (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B15" ref-type="bibr">15</xref>). In line with this, on the circulating T cells, which are almost exclusively of maternal origin, the expression of IL7R&#x003b1; showed a bimodal pattern. This is probably due to the downregulation of CD127 on CD8+ T cells as they progress through the effector stages (<xref rid="B16" ref-type="bibr">16</xref>) and explains the observed impaired IL-7 signaling of the CD3+CD4- subset (<xref ref-type="fig" rid="F2">Figure 2</xref>). However, these cells could provide some degree of immune response, protecting from severe infections and, in some infants, leading to GVHD with cutaneous involvement (rashes, erythrodermia, alopecia), liver injury involvement (hepatosplenomegaly with elevated liver enzymes, cholestasis) and hematologic abnormalities such as eosinophilia, thrombocytopenia and hemophagocytosis. Interestingly, it has been reported in SCID patients that an attenuated or absent alloreactive response <italic>in vivo</italic> correlates with a preponderance of circulating maternal CD8+ T cells, whereas the risk and severity of GVHD is associated with circulating maternal CD4+ T cells (<xref rid="B17" ref-type="bibr">17</xref>). Our patient, who almost exclusively had circulating maternal CD8+ T cells, showed clinical and histological evidence of mild GVHD that completely resolved after a short course of corticosteroid therapy.</p><p>Moreover, our patient showed a hypergammaglobulinemia with normal antibody titers to some vaccine antigens. Hypergammaglobulinaemia was also reported in two other children with IL-7R&#x003b1;-deficient SCID and maternal engraftment (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>). Considering the age of our patient it is unlikely that these levels could reflect the presence of maternally derived IgG, but it could rather be a hallmark of this atypical phenotype. Moreover, in line with previous reports describing a leaky phenotype due to IL-7R&#x003b1; hypomorphic mutations (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>), our patient suffered from clinical features typically suggestive of immunedysregulation (such as thrombocytopenia and hypergammaglobulinemia), probably due to defective tolerance mechanisms (<xref rid="B18" ref-type="bibr">18</xref>).</p><p>The diagnosis of SCID is still a challenge in patients with atypical onset and an unusual clinical and immunological phenotype. Our report highlights the atypical clinical presentation of SCID due to two novel compound mutations of <italic>IL7R</italic>&#x003b1;. In the present case, a combination of self-tolerance perturbation, expressed as maternal engraftment and autoimmune manifestations, delayed the SCID diagnosis. Such a clinical scenario, characterized by early onset autoimmune diseases, isolated CD4-penia despite normal total T cell count and hypergammaglobulinemia, should guide physicians toward proceeding to an NGS approach in order to identify pathogenic variants of atypical PID (<xref rid="B19" ref-type="bibr">19</xref>).</p></sec><sec id="s5"><title>Concluding Remarks</title><p>In conclusion, this report describes an atypical clinical and immunological presentation of IL-7R&#x003b1; deficiency. It is important to alert clinicians to consider a diagnosis of IL-7R&#x003b1; deficiency even in patients with a normal T-cell count and an absence of classical clinical presentation of SCID. Patients with SCID might lack the functional immunity required to reject circulating maternal T cells, resulting in persistent maternal engraftment in up to 40% of patients. Since a diagnostic delay in these patients may be fatal, clinicians should be aware that immune dysregulation manifestations and maternal engraftment should lead to an investigation for possible PID. In this context, NGS techniques play an important role in addressing the diagnosis.</p></sec><sec sec-type="data-availability" id="s6"><title>Data Availability Statement</title><p>All relevant datasets for this study are included in the article/<xref ref-type="sec" rid="s10">Supplementary Material</xref>.</p></sec><sec id="s7"><title>Ethics Statement</title><p>All procedures performed in the study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration. Written informed consent, following standard ethical procedures with approval of the Children's Hospital Bambino Ges&#x000f9; Ethical Committee, was obtained from the parents of the patient for the publication of the case report and any potentially-identifying information.</p></sec><sec id="s8"><title>Author Contributions</title><p>PZ and AF wrote the manuscript. CCi, SD, GD, MC, CS, and SG performed the experiments and analyzed the data. CCi, SD, GD, PR, PP, SG, and CCa contributed to the data interpretation. PZ, DA, NC, MD, SL, PM, MA, PR, PP, CCa, and AF followed up on the patient. All authors reviewed and approved the manuscript.</p><sec><title>Conflict of Interest</title><p>SG is CEO of the company GenomeUp SRL. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><ack><p>The authors thank the patient, her parents and the Ospedale Pediatrico Bambino Ges&#x000f9; staff for their participation in this study.</p></ack><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This work was funded by the Italian TELETHON foundation (grant number GGP15109), the Italian Ministero della Salute (NET-2011-02350069), and Ospedale Pediatrico Bambino Ges&#x000f9; Ricerca Corrente (201702P003966) and (RC2019.1.6_FINOCCHI).</p></fn></fn-group><sec sec-type="supplementary-material" id="s10"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2019.02471/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2019.02471/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SM1"><media xlink:href="Image_1.JPEG"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM2"><media xlink:href="Image_2.JPEG"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>A</given-names></name></person-group>. <article-title>Severe combined immunodeficiencies (SCID)</article-title>. <source>Clin Exp Immunol.</source> (<year>2000</year>) <volume>122</volume>:<fpage>143</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2249.2000.01359.x</pub-id><?supplied-pmid 11091267?><pub-id pub-id-type="pmid">11091267</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzucchelli</surname><given-names>R</given-names></name><name><surname>Durum</surname><given-names>SK</given-names></name></person-group>. <article-title>Interleukin-7 receptor expression: intelligent design</article-title>. <source>Nat Rev Immunol.</source> (<year>2007</year>) <volume>7</volume>:<fpage>144</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1038/nri2023</pub-id><?supplied-pmid 17259970?><pub-id pub-id-type="pmid">17259970</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckley</surname><given-names>RH</given-names></name></person-group>. <article-title>The multiple causes of human SCID</article-title>. <source>J Clin Invest.</source> (<year>2004</year>) <volume>114</volume>:<fpage>1409</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1172/JCI200423571</pub-id><?supplied-pmid 15545990?><pub-id pub-id-type="pmid">15545990</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zago</surname><given-names>CA</given-names></name><name><surname>Jacob</surname><given-names>CM</given-names></name><name><surname>de Albuquerque Diniz</surname><given-names>EM</given-names></name><name><surname>Lovisolo</surname><given-names>SM</given-names></name><name><surname>Zerbini</surname><given-names>MC</given-names></name><name><surname>Dorna</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Autoimmune manifestations in SCID due to <italic>IL7R</italic> mutations: Omenn syndrome and cytopenias</article-title>. <source>Hum Immunol.</source> (<year>2014</year>) <volume>75</volume>:<fpage>662</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.humimm.2014.04.006</pub-id><?supplied-pmid 24759676?><pub-id pub-id-type="pmid">24759676</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leiding</surname><given-names>JW</given-names></name><name><surname>Sriaroon</surname><given-names>P</given-names></name><name><surname>Ly</surname><given-names>JM</given-names></name><name><surname>Petrovic</surname><given-names>A</given-names></name><name><surname>Howard</surname><given-names>DL</given-names></name><name><surname>Shamblott</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Hypomorphic interleukin-7 receptor &#x003b1;-chain mutations and T-cell deficiency: a delay in diagnosis</article-title>. <source>Ann Allergy Asthma Immunol.</source> (<year>2015</year>) <volume>115</volume>:<fpage>1</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.anai.2015.04.024</pub-id><?supplied-pmid 26123418?><pub-id pub-id-type="pmid">26123418</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giliani</surname><given-names>S</given-names></name><name><surname>Bonfim</surname><given-names>C</given-names></name><name><surname>de Saint Basile</surname><given-names>G</given-names></name><name><surname>Lanzi</surname><given-names>G</given-names></name><name><surname>Brousse</surname><given-names>N</given-names></name><name><surname>Koliski</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Omenn syndrome in an infant with <italic>IL7RA</italic> gene mutation</article-title>. <source>J Pediatr.</source> (<year>2006</year>) <volume>148</volume>:<fpage>272</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpeds.2005.10.004</pub-id><?supplied-pmid 16492442?><pub-id pub-id-type="pmid">16492442</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>SM</given-names></name><name><surname>Ege</surname><given-names>M</given-names></name><name><surname>Pottharst</surname><given-names>A</given-names></name><name><surname>Schulz</surname><given-names>AS</given-names></name><name><surname>Schwarz</surname><given-names>K</given-names></name><name><surname>Friedrich</surname><given-names>W</given-names></name></person-group>. <article-title>Transplacentally acquired maternal T lymphocytes in severe combined immunodeficiency: a study of 121 patients</article-title>. <source>Blood</source>. (<year>2001</year>) <volume>98</volume>:<fpage>1847</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1182/blood.V98.6.1847</pub-id><?supplied-pmid 11535520?><pub-id pub-id-type="pmid">11535520</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The UniProt Consortium</collab></person-group>
<article-title>UniProt: the universal protein knowledgebase</article-title>. <source>Nucleic Acids Res.</source> (<year>2018</year>) <volume>46</volume>:<fpage>2699</fpage>
<pub-id pub-id-type="doi">10.1093/nar/gky092</pub-id><pub-id pub-id-type="pmid">29425356</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>HM</given-names></name><name><surname>Westbrook</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name></person-group>
<article-title>The protein data bank</article-title>. <source>Nucleic Acids Res.</source> (<year>2000</year>) <volume>28</volume>:<fpage>235</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1093/nar/28.1.235</pub-id><pub-id pub-id-type="pmid">10592235</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeLano</surname><given-names>WL</given-names></name></person-group>
<article-title>Pymol: An open-source molecular graphics tool</article-title>. <source>CCP4 Newsl Protein Crystallogr.</source> (<year>2002</year>) <volume>40</volume>:<fpage>82</fpage>&#x02013;<lpage>92</lpage>.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pires</surname><given-names>DEV</given-names></name><name><surname>Ascher</surname><given-names>DB</given-names></name><name><surname>Blundell</surname><given-names>TL</given-names></name></person-group>
<article-title>mCSM: predicting the effect of mutations in proteins using graph-based signatures</article-title>. <source>Bioinformatics.</source> (<year>2014</year>) <volume>30</volume>:<fpage>335</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btt691</pub-id><pub-id pub-id-type="pmid">24281696</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>K</given-names></name><name><surname>Green</surname><given-names>TD</given-names></name><name><surname>Roberts</surname><given-names>JL</given-names></name><name><surname>Sajaroff</surname><given-names>E</given-names></name><name><surname>Cooney</surname><given-names>M</given-names></name><name><surname>Parrott</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Unusual clinical and immunologic manifestations of transplacentally acquired maternal T cells in severe combined immunodeficiency</article-title>. <source>J Allergy Clin Immunol.</source> (<year>2007</year>) <volume>120</volume>:<fpage>423</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2007.02.047</pub-id><?supplied-pmid 17481714?><pub-id pub-id-type="pmid">17481714</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giliani</surname><given-names>S</given-names></name><name><surname>Mori</surname><given-names>L</given-names></name><name><surname>de Saint Basile</surname><given-names>G</given-names></name><name><surname>Le Deist</surname><given-names>F</given-names></name><name><surname>Rodriguez-Perez</surname><given-names>C</given-names></name><name><surname>Forino</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Interleukin-7 receptor alpha (IL-7Ralpha) deficiency: cellular and molecular bases</article-title>. Analysis of clinical, immunological, and molecular features in 16 novel patients. <source>Immunol Rev.</source> (<year>2005</year>) <volume>203</volume>:<fpage>110</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1111/j.0105-2896.2005.00234.x</pub-id><?supplied-pmid 15661025?><pub-id pub-id-type="pmid">15661025</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bayer</surname><given-names>DK</given-names></name><name><surname>Martinez</surname><given-names>CA</given-names></name><name><surname>Sorte</surname><given-names>HS</given-names></name><name><surname>Forbes</surname><given-names>LR</given-names></name><name><surname>Demmler-Harrison</surname><given-names>GJ</given-names></name><name><surname>Hanson</surname><given-names>IC</given-names></name><etal/></person-group>. <article-title>Vaccine-associated varicella and rubella infections in severe combined immunodeficiency with isolated CD4 lymphocytopenia and mutations in <italic>IL7R</italic> detected by tandem whole exome sequencing and chromosomal microarray</article-title>. <source>Clin Exp Immunol.</source> (<year>2014</year>) <volume>178</volume>:<fpage>459</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1111/cei.12421</pub-id><?supplied-pmid 25046553?><pub-id pub-id-type="pmid">25046553</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khanolkar</surname><given-names>A</given-names></name><name><surname>Wilks</surname><given-names>JD</given-names></name><name><surname>Jennings</surname><given-names>LJ</given-names></name><name><surname>Davies</surname><given-names>JL</given-names></name><name><surname>Zollett</surname><given-names>JA</given-names></name><name><surname>Lott</surname><given-names>LL</given-names></name><etal/></person-group>. <article-title>Signaling impairments in maternal T cells engrafted in an infant with a novel IL-2 receptor &#x003b3; mutation</article-title>. <source>J Allergy Clin Immunol.</source> (<year>2015</year>) <volume>135</volume>:<fpage>1093</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2015.02.012</pub-id><?supplied-pmid 25843602?><pub-id pub-id-type="pmid">25843602</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaunders</surname><given-names>JJ</given-names></name><name><surname>L&#x000e9;vy</surname><given-names>Y</given-names></name><name><surname>Seddiki</surname><given-names>N</given-names></name></person-group>. <article-title>Exploiting differential expression of the IL-7 receptor on memory T cells to modulate immune responses</article-title>. <source>Cytokine Growth Factor Rev.</source> (<year>2014</year>) <volume>25</volume>:<fpage>391</fpage>&#x02013;<lpage>401</lpage>. <pub-id pub-id-type="doi">10.1016/j.cytogfr.2014.07.012</pub-id><?supplied-pmid 25130296?><pub-id pub-id-type="pmid">25130296</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahlstrom</surname><given-names>J</given-names></name><name><surname>Patel</surname><given-names>K</given-names></name><name><surname>Eckhert</surname><given-names>E</given-names></name><name><surname>Kong</surname><given-names>D</given-names></name><name><surname>Horn</surname><given-names>B</given-names></name><name><surname>Cowan</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Transplacental maternal engraftment and posttransplantation graft-versus-host disease in children with severe combined immunodeficiency</article-title>. <source>J Allergy Clin Immunol.</source> (<year>2017</year>) <volume>139</volume>:<fpage>628</fpage>&#x02013;<lpage>33.e10</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2016.04.049</pub-id><?supplied-pmid 27444177?><pub-id pub-id-type="pmid">27444177</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azizi</surname><given-names>G</given-names></name><name><surname>Pouyani</surname><given-names>MR</given-names></name><name><surname>Abolhassani</surname><given-names>H</given-names></name><name><surname>Sharifi</surname><given-names>L</given-names></name><name><surname>Dizaji</surname><given-names>MZ</given-names></name><name><surname>Mohammadi</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Cellular and molecular mechanisms of immune dysregulation and autoimmunity</article-title>. <source>Cell Immunol.</source> (<year>2016</year>) <volume>310</volume>:<fpage>14</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellimm.2016.08.012</pub-id><?supplied-pmid 27614846?><pub-id pub-id-type="pmid">27614846</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cifaldi</surname><given-names>C</given-names></name><name><surname>Brigida</surname><given-names>I</given-names></name><name><surname>Barzaghi</surname><given-names>F</given-names></name><name><surname>Zoccolillo</surname><given-names>M</given-names></name><name><surname>Ferradini</surname><given-names>V</given-names></name><name><surname>Petricone</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Targeted NGS platforms for genetic screening and gene discovery in primary immunodeficiencies</article-title>. <source>Front. Immunol.</source> (<year>2019</year>) <volume>10</volume>:<fpage>316</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2019.00316</pub-id><pub-id pub-id-type="pmid">31031743</pub-id></mixed-citation></ref></ref-list></back></article>